4.5 Article

Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease

期刊

EUROPEAN RESPIRATORY REVIEW
卷 30, 期 159, 页码 -

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/16000617.0193-2020

关键词

-

资金

  1. Intramural Research Program, National Human Genome Research Institute, National Institutes of Health (NIH)

向作者/读者索取更多资源

Pulmonary fibrosis is a progressive interstitial lung disease with poor prognosis. Genetic studies of Hermansky-Pudlak syndrome (HPS) have provided insights into the pathogenesis of the disease, revealing a high prevalence of pulmonary fibrosis in three genetic types of HPS. HPS pulmonary fibrosis shares some clinical features with idiopathic pulmonary fibrosis but differs in age of onset and CT findings.
Pulmonary fibrosis is a progressive interstitial lung disease of unknown aetiology with a poor prognosis. Studying genetic diseases associated with pulmonary fibrosis provides insights into the pathogenesis of the disease. Hermansky-Pudlak syndrome (HPS), a rare autosomal recessive disorder characterised by abnormal biogenesis of lysosome-related organelles, manifests with oculocutaneous albinism and excessive bleeding of variable severity. Pulmonary fibrosis is highly prevalent in three out of 10 genetic types of HPS (HPS-1, HPS-2 and HPS-4). Thus, genotyping of individuals with HPS is clinically relevant. HPS-1 tends to affect Puerto Rican individuals due to a genetic founder effect. HPS pulmonary fibrosis shares some clinical features with idiopathic pulmonary fibrosis (IPF), including dyspnoea, cough, restrictive lung physiology and computed tomography (CT) findings of fibrosis. In contrast to IPF, HPS pulmonary fibrosis generally affects children (HPS-2) or middle-aged adults (HPS-1 or HPS-4) and may be associated with ground-glass opacification in CT scans. Histopathology of HPS pulmonary fibrosis, and not IPF, shows vacuolated hyperplastic type II cells with enlarged lamellar bodies and alveolar macrophages with lipofuscin-like deposits. Antifibrotic drugs approved as treatment for IPF are not approved for HPS pulmonary fibrosis. However, lung transplantation has been performed in patients with severe HPS pulmonary fibrosis. HPS pulmonary fibrosis serves as a model for studying fibrotic lung disease and fibrosis in general.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据